Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2023-12-10 Director's Dealing
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 2 pages 281.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including performance rights and shares acquired, disposed, and held before and after the change. The document is a formal notification of insider share transactions by a director, which fits the definition of 'Director's Dealing' filings. The document length is 3593 characters, which is consistent with a detailed insider transaction report rather than a brief announcement or other report types. There is no financial performance data or management discussion, so it is not an Annual Report or Earnings Release. It is not a regulatory filing or announcement of a report but a direct report of director share transactions.
2023-12-10 English
Update - Notification of buy-back - MYX 6 pages 27.7KB
Transaction in Own Shares Classification · 100% confidence The document is a detailed notification about a company's on-market share buy-back activity, including daily updates on the number of securities bought back, prices paid, broker information, and key dates. It specifically states it is a 'Notification of buy-back' and provides daily buy-back notifications as required by listing rules. This matches the description of a 'Transaction in Own Shares' filing, which reports the company's buy-back or sale of its own shares. The document is not an announcement of a report, nor is it a financial report or regulatory certification. Therefore, the correct classification is POS (Transaction in Own Shares). The document length and detail support a high confidence score.
2023-12-07 English
Update - Notification of buy-back - MYX 6 pages 27.7KB
Transaction in Own Shares Classification · 100% confidence The document is a detailed notification of a daily buy-back activity by Mayne Pharma Group Limited. It includes specifics such as the number of securities bought back, prices paid, dates, broker information, and regulatory compliance details related to the on-market buy-back program. The content is focused on the company's repurchase of its own shares rather than financial results, management changes, or other report types. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on share repurchase activities. The document length and detail confirm it is not a brief announcement or a report publication notice but the actual notification of buy-back transactions.
2023-12-06 English
Update - Notification of buy-back - MYX 6 pages 27.7KB
Transaction in Own Shares Classification · 100% confidence The document is a notification of a buy-back by Mayne Pharma Group Limited. It provides detailed information about the on-market buy-back, including the number of securities bought back, prices paid, dates, and broker details. The content is focused on the company's share repurchase activity rather than financial results, management changes, or regulatory filings. The document length is about 5270 characters, which is sufficient for a detailed buy-back report. Therefore, this fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2023-12-05 English
Change of Director's Interest Notice 2 pages 266.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in shareholding, including the number of shares held before and after the transaction, the nature of the transaction (on-market trade), and dates. There is no financial performance data, earnings information, or report content. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing' filings. The document length is 3127 characters, which is consistent with a notice rather than a full report. Therefore, the correct classification is DIRS (Director's Dealing).
2023-12-05 English
Update - Notification of buy-back - MYX 6 pages 27.7KB
Transaction in Own Shares Classification · 100% confidence The document is a detailed notification of a share buy-back by Mayne Pharma Group Limited. It includes specifics such as the type of buy-back (on-market), dates, number of securities bought back, prices paid, broker information, and compliance with listing rules. The content is focused on the company's repurchase of its own shares and daily updates on the buy-back activity. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on the company buying back or selling its own shares. The document is not an announcement of a report, nor is it a financial report or regulatory certification. Therefore, the correct classification is POS with high confidence.
2023-12-04 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.